loading page

The Impact of Sublingual Immunotherapy on Quality of Life in Allergy Rhinitis Patients
  • +1
  • Luqman Rosla,
  • Salina Hussain,
  • Farah Dayana Zahedi,
  • Mohd Syazwan Mohamad Anuar
Luqman Rosla
Pusat Perubatan Universiti Kebangsaan Malaysia
Author Profile
Salina Hussain
Pusat Perubatan Universiti Kebangsaan Malaysia
Author Profile
Farah Dayana Zahedi
Pusat Perubatan Universiti Kebangsaan Malaysia
Author Profile
Mohd Syazwan Mohamad Anuar
National Defence University of Malaysia
Author Profile

Abstract

Introduction: Immunotherapy has proven its efficacy in multiple randomized control trials (RCT) in treating allergic rhinitis (AR) as it induces induces long term remission after discontinuation and prevent new sensitization. Objective: Our aim is to look into earliest improvement of quality of life (QOL) in AR patient treated with Sublingual immunotherapy (SLIT). Methodology: Patients who were sensitized to dust mites (Dermatophagoides farinae, Dermatophagoides pteronyssinus and Blomia tropicalis) were enrolled into the study. All patients were treated with SLIT for 6 months. The patients were assessed using rhinoconjunctivitis quality of life questionnaires (RQLQ) and peak nasal inspiratory flow (PNIF) pre-treatment at 1, 3 and 6 months post SLIT. The usage of intranasal corticosteroids (INS) and antihistamine were documented in medication diary. The data for pre and post treatment for RQLQ results were analysed using paired T-test and medication diary were analysed using ANOVA test. Results: A total of 53 patients were enrolled in the study. The mean RQLQ score showed significant result at 3 and 6 months post SLIT (p<0.05). Significant improvement seen in the mean PNIF value pre-treatment (81.54 L/min ±29.36 ) compared to mean PNIF value at 3 months (92.0L/min ±29.03 ) and 6 months (96.13L/min ±26.67) post SLIT (p<0.05). The dependency of patients towards pharmacotherapy also showed a significant reduction at 3 and 6 months post SLIT (p<0.05). Conclusion: Our study showed a significant improvement of patients’ quality of life as early as 3 months of post SLIT treatment.